Transcend Capital Advisors LLC Has $336,000 Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Transcend Capital Advisors LLC trimmed its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 7.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 997 shares of the medical equipment provider’s stock after selling 85 shares during the period. Transcend Capital Advisors LLC’s holdings in Intuitive Surgical were worth $336,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its position in Intuitive Surgical by 0.3% in the 4th quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 8,899 shares of the medical equipment provider’s stock valued at $3,002,000 after buying an additional 27 shares during the last quarter. Liberty Capital Management Inc. raised its holdings in shares of Intuitive Surgical by 3.8% in the fourth quarter. Liberty Capital Management Inc. now owns 815 shares of the medical equipment provider’s stock valued at $275,000 after purchasing an additional 30 shares during the last quarter. Miracle Mile Advisors LLC boosted its holdings in Intuitive Surgical by 2.3% during the fourth quarter. Miracle Mile Advisors LLC now owns 1,438 shares of the medical equipment provider’s stock worth $485,000 after purchasing an additional 32 shares during the last quarter. Ausdal Financial Partners Inc. lifted its position in shares of Intuitive Surgical by 1.5% during the 4th quarter. Ausdal Financial Partners Inc. now owns 2,192 shares of the medical equipment provider’s stock worth $739,000 after buying an additional 33 shares in the last quarter. Finally, Venturi Wealth Management LLC boosted its stake in shares of Intuitive Surgical by 10.7% in the 4th quarter. Venturi Wealth Management LLC now owns 341 shares of the medical equipment provider’s stock worth $115,000 after buying an additional 33 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insiders Place Their Bets

In related news, VP Marshall Mohr sold 108,790 shares of Intuitive Surgical stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the sale, the vice president now owns 26,877 shares in the company, valued at $10,349,795.16. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, Director Alan J. Levy sold 2,000 shares of the stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the transaction, the director now owns 25,319 shares of the company’s stock, valued at approximately $9,385,753.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Marshall Mohr sold 108,790 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the sale, the vice president now owns 26,877 shares in the company, valued at $10,349,795.16. The disclosure for this sale can be found here. In the last 90 days, insiders sold 225,093 shares of company stock worth $87,153,299. 0.80% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Piper Sandler lifted their price target on Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a report on Friday, April 19th. Robert W. Baird reduced their price target on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research report on Friday, April 19th. Stifel Nicolaus lifted their price objective on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. StockNews.com downgraded shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Finally, Truist Financial lifted their price target on shares of Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 24th. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $396.17.

Intuitive Surgical Trading Down 0.3 %

NASDAQ ISRG opened at $374.14 on Tuesday. The firm has a market cap of $132.71 billion, a PE ratio of 67.53, a price-to-earnings-growth ratio of 4.85 and a beta of 1.36. The stock has a 50-day moving average of $386.10 and a 200-day moving average of $347.50. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating the consensus estimate of $1.40 by $0.10. The firm had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The company’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.00 earnings per share. As a group, equities research analysts forecast that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.